Beauty Farm Medical and Health Industry Inc.
美麗田園醫療健康產業有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2373)

INSIDE INFORMATION
LONG TERM SHAREHOLDER RETURN PLANS

This announcement is hereby made by Beauty Farm Medical and Health Industry Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, in order to enhance shareholder value, the Board has resolved to utilize up to HK$1.2 billion on a discretionary basis over the next three years to provide the shareholders (the "**Shareholders**") of the Company with returns either by (i) the declaration of annual dividend in accordance with the Company's prevailing dividend policies, which as disclosed in the announcement in relation to the change of dividend policy dated March 26, 2025 of the Company, is to make distribution by way of ordinary dividend per annum over the next three full financial years of no less than 50% of the Company's net profit attributable to owners of the Company during such year (in the absence of special circumstances); or (ii) by repurchase of the shares (the "**Shares**") of the Company through on-market share repurchase based on the general mandate granted at the Company's annual general meeting held on June 27, 2025 (the "**Existing Repurchase Mandate**") as well as any subsequent mandate granted by the Shareholders to carry out repurchase during period subsequent to the expiration of the Existing Repurchase Mandate.

The Company intends to fund the forgoing plans through its internal resources, and the Company does not expect that the implementation of the plans will have a material adverse impact on the working capital position of the Group. Shareholders and potential investors should note that the Company has been authorized to repurchase 23,579,556 Shares pursuant to the Existing Repurchase Mandate and as of the date of this announcement, the Company has already repurchased an aggregate of 605,500 Shares pursuant to the Existing Repurchase Mandate.

Shareholders and potential investors of the Company are advised that the implementation of the forgoing plans are subject to the sole discretion of the Directors. Any dividend declarations and share repurchase arrangements will be made based on, among other considerations, the Group's operating performance and major mergers and acquisitions, while the repurchase of any Shares will be subject to the market conditions and compliance with applicable rules and regulations, no assurance can be given as to the timing, quantity or price of any dividend to be declared or repurchase to be made.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Beauty Farm Medical and Health Industry Inc.
Li Yang
Chairman and executive Director

Hong Kong, November 4, 2025

As at the date of this announcement, the Board comprises Mr. Li Yang as Chairman and executive director, Mr. Lian Songyong as Vice Chairman and executive director, Ms. Li Fangyu, Mr. Gao Jianming and Ms. Yi Lin as non-executive directors and Mr. Fan Mingchao, Mr. Liu Teng and Mr. Jiang Hua as independent non-executive directors.